A review of the prevention and treatment of venous thromboembolism

Formulary

Volumn 45, Issue 3, 2010, Pages 91-100

  Wood, Bryan ^a   Fitzatrick, Lori ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; D DIMER; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; TINZAPARIN; WARFARIN;

ANAPHYLAXIS; AUTOIMMUNE DISEASE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; ECHOGRAPHY; ECZEMA; FEVER; GENETIC DISORDER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATOMA; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; IMPEDANCE PLETHYSMOGRAPHY; INJECTION SITE IRRITATION; INTERNATIONAL NORMALIZED RATIO; LEG PAIN; LEG SWELLING; LIVER FUNCTION TEST; LUNG EDEMA; LUNG EMBOLISM; MORTALITY; NAUSEA; NEOPLASM; ORAL CONTRACEPTION; PAIN; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; PNEUMONIA; POSTTHROMBOSIS SYNDROME; PROPHYLAXIS; PROTEIN DEFICIENCY; REVIEW; RISK FACTOR; SCORING SYSTEM; SKIN DISCOLORATION; SPINAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT DURATION; VEIN INSUFFICIENCY; VENOUS THROMBOEMBOLISM;

EID: 77954798513     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Biiller H, Agnelli G, Hull R, Hyers TM, Prins MH3 Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):401S-428S.
2. White R. The epidemiology of venous thromboembolism. Circulation. 2003;107(suppl 1):I4-I8.
3. Silverstein M, Heit J, Mohr D, Petterson T, O'Fallon W, Melton L. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch IntemMed. 1998;158:585-593.
4. Anderson F Jr., Spencer F. Risk factors for venous thromboembolism. Circulation. 2003;107: 19-116.
5. Hansson P, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.
6. Heit J, Mohr D, Silverstein M, Petterson T, O'Fallon W, Melton L. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch IntemMed. 2000;160:761-768. (Pubitemid 30165236)
7. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis: a randomized study. Acta Med Scand. 1985;217:547-552.
8. Lee A, Levine M. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(suppl 1):I17-I21.
9. Haines S, Witt D, Nutescu E. Venous thromboembolism. In: DiPiro JT, et al. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill, 2008:331-371.
10. Thomas R. Hypercoagulability syndromes. Arch IntemMed. 2001;161:2433-2439.
11. Rosendaal F, Helmerhorst F, Vandenbroucke J. Female hormones and thrombosis. Arterioscler Thromb Vase Biol. 2002;22:201-210.
12. Scurr J, Machin S, Bailey-King S3 Mackie U3 McDonald S, Smith PD. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights; a randomised trial. Lancet. 2001;357:1485-1489.
13. Lapostolle F, Surget V, Borron S, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001;345:779-783.
14. Turpie A, Chin B, Lip G. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325:887-890.
15. KearonC Naturalhistory of venous thromboembolism. Circulation. 2003;107(suppl 1):I22-I30.
16. Dahlback B. Blood coagulation. Lancet. 2000;355:1627-1632.
17. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94:439-444.
18. Turkstra F, Kuijer PM, van Beek EJ, Brandjes DP, ten Cate JW, Buller HR. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann IntemMed. 1997;126:775-781.
19. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med. 2000;160:159-164.
20. Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998;128:1-7.
21. Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med. 1986;314:823-828.
22. Landaw SA, Bauer KA. Approach to the diagnosis and therapy of deep vein thrombosis. In: UpToDate, Leung, LLK, UpToDate, Waltham, MA, 2009.
23. Alikhan R, Cohen AT, Combe S, et al; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164:963-968.
24. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med, 2009;169:610-615.
25. Goodacre S, Sutton AJ, Sampson FC. Metaanalysis: the value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med. 2005;143:129-139.
26. Hull RD, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation. 1981;64:622-625.
27. Kearon C, Julian JA, Math M, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Guidelines. Ann Intern Med. 1998;128:663-667.
28. Pineo GF. Prevention of venous thromboembolic disease in medical patients. In: UpToDate, Leung, LLK, UpToDate, Waltham, MA, 2009.
29. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350:1795-1798.
30. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227-1235.
31. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Camerata AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S-545S. (Pubitemid 351892971)
32. Lovenox (enoxaparin) [package insert]. Bridge-water, NJ: Sanofi-Aventis; 2008.
33. Fragmin (dalteparin) [package insert]. Wood-cliff Lake, NJ: Eisai Inc; 2008.
34. Innohep (tinzaparin) [package insert]. Ballerup, Denmark: LEO Pharma; 2009.
35. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low-molecular-weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004(4): CD001100.
36. Dolovich LR, Ginsberg JS, Douketis JD, Hol-brook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160:181-188.
37. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 2001;344:626-631.
38. Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI Group. Thromb Haemost. 1998;79:897-901.
39. Holmostrom M, Berglund MC, Granquist S, Bratt G, Tornebohm F, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res. 1992;67:49-55.
40. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost. 2001;86:980-984.
41. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2005;165:733-738.
42. Arixtra (fondaparinux) [packageinsert]. Research Triangle Park, NC: GlaxoSmithKline.; 2008.
43. Buller HR, Davidson BL, Decousus H, et al; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867-873.
44. Lu J, Knudson MM, Bir N, Kallet R, Atkinson K. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study. J Am Coll Surg. 2009; 209:589-594.
45. Heparin [package insert]. Cincinnati, OH: Cel-sus Laboratories; 2005.
46. Coutre S. Heparin-induced thrombocytopenia. In: UpToDate, Leung, LLK, UpToDate, Waltham, MA, 2009.
47. Levine M, Gent M, Hirsh J, et al. A comparison of low-mokcular-weight heparin administered primarily at home with unfractionated heparin administered m the hospital tor proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
48. Kearon C, Ginsberg J, Julian JA, et al; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006;296:935-942.
49. Coumadin (warfarin) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2007.
50. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):160S-198S. (Pubitemid 351892967)
51. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049-2056.
52. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
53. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S-400S.
54. Zhan C, Miller M. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003;290:1868-1874.
55. Best A, Williams S, Crazier A, Bhatt R, Gregg PJ, Hui AC. Graded compression stockings in elective orthopaedic surgery. An assessment of the in vivo performance of commercially available stockings in patients having hip and knee arthroplasty. J Bone Joint Surg Br. 2000;82:116-118.
56. Blanchard J, Meuwly J, Leyvraz P, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br. 1999;81:654-659.
57. Freedman K, Brookenthal K, Fitzgerald R, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929-938.
58. Lachiewicz P, Kelley S, Haden L. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomized study. J Bone Joint Surg Br. 2004;86:1137-1141.
59. Francis C, Pellegrini V Jr., Marder V, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911-2915.
60. Handoll HHG, Farrar MJ, McBirnie J, Ty-therleigh-Strong GM, Milne A A, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev. 2002(4):CD000305.